CD19 and lymphoma: We demonstrate that the variant SF05 enabledthedetermination of the monovalent affinity between CD19 and a clinicallyapproved FMC63-based CAR, as well as monitoring and phenotypic characterizationof CD19-directed CAR-T cells in the blood of lymphoma patients.